Free cookie consent management tool by TermsFeed Privacy Suite

Press Releases

Press Release

St. Baldrick’s Foundation Welcomes Julia Glade Bender, M.D., of Memorial Sloan Kettering to its Board of Directors

May 25, 2023

Media Contact:
Traci Johnson

New York, NY (May 24, 2023) – The St. Baldrick’s Foundation, the largest charity funder of childhood cancer research grants, announces the appointment of Julia Glade Bender, M.D., of Memorial Sloan Kettering (MSK), to its Board of Directors.

Dr. Glade Bender is a pediatric oncologist, translational clinical trialist and provides scientific leadership for early-phase clinical trials sponsored by the National Cancer Institute (NCI), the Children’s Oncology Group (COG), and other small consortiums at a national level.

Since 2004, Dr. Glade Bender has served as an active member of the COG Developmental Therapeutics Committee (DVL) and the DVL liaison to the Neuroblastoma and Bone Sarcoma Steering Committees. Additionally, she serves as a consultant to the Pediatric Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA), sits on the Steering Committee for the Pediatric NCI-MATCH (Pediatric Molecular Analysis for Therapy Choice), and serves as the COG Chair for the ECOG-ACRIN-NCI-ComboMATCH.

As a Yale University and University of Pennsylvania School of Medicine graduate, Dr. Glade Bender completed her pediatric residency at the Mount Sinai Hospital and her hematology-oncology fellowship at Memorial Sloan Kettering (MSK). In 2018, she returned to MSK as a professor and Vice Chair for Clinical Research in the Department of Pediatrics (MSK Kids), and in 2021, she helped found and now co-leads the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers.

Dr. Glade Bender’s clinical practice concentrates on children, adolescents, and young adults with relapsed, refractory, and high-risk solid tumors. With a passion for training the next generation of translational clinician-scientists, Dr. Glade Bender has made it her duty to practice alongside young investigators in the pre-clinical and clinical leadership of early phase studies.

“We are pleased to welcome Dr. Julia Glade Bender to our Board of Directors. As a new member, she will bring a unique approach to our Board and Scientific Advisory Program,” says CEO of St. Baldrick’s Foundation, Kathleen Ruddy. “One of her strengths is studying the entire childhood cancer landscape to identify obstacles to progress and developing strategies to accelerate progress for every child. Dr. Glade Bender’s expertise will be a valuable asset to the Foundation as we pursue our mission to fund research to find cures for all childhood cancers.”

To learn more about St. Baldrick’s, its mission, and board members, visit and connect on Facebook, Twitter, Instagram, LinkedIn, or YouTube.

About St. Baldrick’s Foundation
Every 2 minutes, a child somewhere in the world is diagnosed with cancer. In the U.S., 1 in 5 will not survive. The St. Baldrick’s Foundation, the largest charity funder of childhood cancer research grants, is on a mission to Conquer Kids’ Cancer by supporting the most promising research to find cures and better treatments for all childhood cancers. When you give to St. Baldrick’s, you don’t just give to one hospital – you support virtually every institution with the expertise to treat kids with cancer across the U.S. St. Baldrick’s ensures that children fighting cancer now — and those diagnosed in the future — will have access to the most cutting-edge treatment, by supporting every stage of research, from new ideas in the lab to the training of the next generation of researchers, to lifesaving clinical trials. Visit and help #ConquerKidsCancer.